Skip to content
type1.science
ObservationalActive, not recruitingNCT05515939

Evaluating the InPen in pediatric type 1 diabetes

What this study tests

An observational study of Medtronic's InPen connected insulin pen in adolescents and young adults with T1D per the registry. No results posted; primary completion is estimated November 2026.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-08-20.

Most recent recorded citation date: 2026-08-20. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
People aged 13–21 (inclusive) with type 1 diabetes for more than 6 months, HbA1c above 8% in the prior 3 months, using multiple daily injections (basal-bolus, three or more injections per day). Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted. Active, not recruiting; estimated n=34; started 9 September 2022; primary completion estimated 30 November 2026. Live registry ages are 13–21 (was written as 2–17); lead sponsor is Wayne State University (was written as Stanford). Last update 20 August 2026.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Change in hemoglobin A1c (HbA1c)

The full picture

This observational study asks how a connected pen behaves in real adolescent and young-adult MDI care per the registry (ages 13–21). Until results post, it does not change the site's InPen/MiniMed Go ranking.

Sources

  1. [1]